Fusion proteins composed of an antibody and a mutein

Abstract

The present invention relates to the field of Biotechnology and Immuno-oncology. Fusion proteins comprising an interleukin 2 agonist mutein linked to an immunoglobulin via a linker are disclosed. These fusion proteins are useful in the treatment of cancer given their superior properties when compared to other similar ones based on no-alpha IL-2 muteins, by simultaneously preserving the ability of antibodies to make ADCC and CDC and, in addition, activating NK cells and CD8+, without expand regulatory T cells. The convergence of these properties results in fusion proteins with antitumor properties superior to the parental antibodies, and even to their combination with the no-alpha mutein.

Dependencies are inferred from the claim text.